How To Control BP (BPJS MLG 14 Okt 2014) DR Atma
How To Control BP (BPJS MLG 14 Okt 2014) DR Atma
How To Control BP (BPJS MLG 14 Okt 2014) DR Atma
Atma Gunawan
Subspecialist of Nephrology and
Hypertension
Blood Pressure Classification
(JNC VII ; office BP)
BP Classification SBP mmHg DBP mmHg
Hypertension:
SBP >140 mmHg DBP >90 mmHg
* The blood pressure (BP) category is defined by the highest level of BP, whether systolic or diastolic. Isolated
systolic hypertension should be graded 1, 2, or 3 according to systolic BP values in the ranges indicated.
Who should measure BP ?
190
+20% Systolic
170 +38%
Blood Pressure (mm Hg)
150
130
110
+57% +38%
90 Diastolic
70
0 3 6 9 12 15 18 21
Clock Time (hours)
Ambulatory BP
The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) - J Hypertension 2013;31:1281-1357
Medical Education & Information for all Media, all Disciplines, from all over
the World Powered by
11-year risk of cardiovascular mortality for
10mm Hg increase in office, home, and
ambulatory BP (Pamela Study, n= 1412)
J Hypertension 2007;25:2193-98
Treatment strategies in white-coat
and masked hypertension
(ESH-ESC 2013)
BP target JNC VIII (2014)
Aged 18 yrs to <60 yrs , CKD,
DM :
SBP < 140 mmHg
DBP < 90 mmHg
Aged 60 yrs :
SBP <150 mmHg
DBP <90 mmHg
JNC VIII Guideline Management
Algorithm
CKD
Quit smoking
The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) - J Hypertension 2013;31:1281-1357
Medical Education & Information for all Media, all Disciplines, from all over
the World Powered by
Guidelines Worldwide Acknowledge That Most Patients
Need Combination Therapy to Achieve BP Goals
Many patients will require more than one drug to achieve adequate
BP control
NICE
Chobanian et al. JAMA. 2003;289:25602572; Mancia et al. Eur Heart J. 2007;28:14621536; http://www.nice.org.uk/
download.aspx?o=CG034fullguideline (accessed January 2010); Ogihara et al. Hypertens Res. 2009;32:3107.
Multiple antihypertensive agents
are needed to achieve target BP
Number of antihypertensive agents
Trial Target BP (mmHg) 1 2 3 4
The extra blood pressure reduction from combining drugs from 2 different classes is
approximately 5 times greater than doubling the dose of 1 drug
Thiazide diuretics
-blockers Angiotensin-receptor
blockers
Other Calcium
antihypertensives antagonists
ACE inhibitors
Green continuous lines: preferred combinations; green dashed line: useful combination (with some limitations); black
dashed lines: possible but less well tested combinations; red continuous line: not recommended combination. Although
verapamil and diltiazem are sometimes used with a beta-blocker to improve ventricular rate control in permanent atrial
fibrillation, only dihydropyridine calcium antagonists should normally be combined with beta-blockers.
The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) - J Hypertension 2013;31:1281-1357
Medical Education & Information for all Media, all Disciplines, from all over
the World Powered by
Ineffective combinations
ONTARGET: ACE-I and ARB are accompanied by a significant
excess of cases of ESRD
ACE-I/ARB and BB : produces little additional blood pressure
reduction compared with either monotherapy. Commonly combined
to reduce reinfarction rates and to improve survival.
BB and diuretic : increase the risk of glucose intolerance, the
development of new-onset diabetes,fatigue, and sexual dysfunction.
BB and antiadrenergic drugs (clonidine,methyldopa,reserpine) : little
effect in lowering BP, frequent exaggerated rebound.
HCT is ineffective if creatinine level > 2.5 mg/dL. Switch to
furosemide.
Doxazosin or spironolactone can be added to triple therapy in
patients with resistant hypertension
Preferred hypertension treatment in specific conditions
Condition Drug
Asymptomatic organ damage
LVH LVH ACE inhibitor, calcium antagonist, ARB
Asymptomatic atherosclerosis Calcium antagonist, ACE inhibitor
Microalbuminuria ACE inhibitor, ARB
Renal dysfunction ACE inhibitor, ARB
Clinical CV event
Previous stroke Any agent effectively lowering BP
Previous myocardial infarction BB, ACE inhibitor, ARB
Angina pectoris BB, calcium antagonist
Heart failure Diuretic, BB, ACE inhibitor, ARB, mineralocorticoid receptor antagonists
Aortic aneurysm BB
Atrial fibrillation, prevention Consider ARB, ACE inhibitor, BB or mineralocorticoid receptor antagonist
Atrial fibrillation, ventricular rate control BB, non-dihydropyridine calcium antagonist
ESRD/proteinuria ACE inhibitor, ARB
Peripheral artery disease ACE inhibitor, calcium antagonist
Other
ISH (elderly) Diuretic, calcium antagonist
Metabolic syndrome ACE inhibitor, ARB, calcium antagonist
Diabetes mellitus ACE inhibitor, ARB
Pregnancy Methyldopa, BB, calcium antagonist
Blacks Diuretic, calcium antagonist
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BB, beta-blocker; BP, blood pressure; CV, cardiovascular; ESRD, end-stage renal
disease;
ISH, isolated systolic hypertension; LVH, left ventricular hypertrophy.
Compelling indications for hypertension treatment
Class Contraindications
Compelling Possible
Diuretics Gout Metabolic syndrome
(thiazides) Glucose intolerance
Pregnancy
Hypercalcemia
Hypokalaemia
A-V, atrio-ventricular; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; LV, left
ventricular.
Secondary hypertension
Secondary causes of hypertension
The most common were renal disease
68%
Endocrine 11%
Renovascular diseases 10%
Clinical features of secondary hypertension
a Age, sex, marital status, religion, past history of smoking were not statistically significant
b BMI = body mass index.
c Figures in parentheses are standard errors.
d Figures in italics are 95% confidence intervals.
e By self-report.
Bulletin of the World Health Organization, 2001, 79 (6)
Obesity and hypertension
Methods
The survey was performed on 5065 hypertensive patients with visceral obesity.
BP control was analyzed on the basis of office and home BP measurements.
Patients reporting non-compliance were excluded from the study.
Results
The percentage of RH was 13.9%. RH was more frequent only in obese with
BMI35 and <40kg/m2 (16.2%) and in morbidly obese individuals (26.5%).
Patients with BMI35 and <40kg/m2 and with morbid obesity were receiving
three-drug therapy more frequently than patients with visceral obesity and
BMI<30kg/m2. A multiple regression analysis revealed that obesity was
associated with RH independent from longer than 5-year period of
antihypertensive therapy, diabetes, smoking cigarettes, cardiovascular disease
and heart failure. The analysis of home BP measurement revealed that in
11.1% of patients RH was in fact white coat hypertension.
Behavioral factors :
- weight loss
- no alcohol and smoking,
and no sedatives before
sleep
- avoidance of supine sleep
position but lateral
decubitus
Spironolactone 25-50 mg/d
Nasal CPAP Continuous positive
airway pressure
Oral dental devices
Surgical procedures :
UPP, nasal
surgery,,tonsilectony,LAUP
Maxiofacial surgery,tracheostomy
Can antihypertensive medications
be
reduced or stopped?
Patients in effective BP control for an
extended period, it may be possible to
reduce the number and dosage of drugs.
Reduction of medications should be made
gradually
BP control is accompanied by healthy
lifestyle
BP should be checked frequently because
of the risk of reappearance of hypertension.
Discontinuation of antihypertensive
therapy
N : 2765